View More Recent Stories

Dec 9, 2024 03:30PM Agios Pharma (AGIO) puts active as share price down 22%

Oct 31, 2024 01:17PM Raymond James Reiterates Outperform Rating on Agios Pharma (AGIO)

Oct 31, 2024 06:32AM Agios Pharma (AGIO) Tops Q3 EPS by $1

Oct 23, 2024 07:07AM Agios Pharma (AGIO) Completes Enrollment of Phase 3 RISE UP Study of Mitapivat in Sickle Cell Disease

Oct 15, 2024 05:59AM Leerink Partners Reiterates Market Perform Rating on Agios Pharma (AGIO)

Oct 10, 2024 08:19AM Raymond James Resumes Agios Pharma (AGIO) at Outperform

Sep 27, 2024 06:37AM Leerink Partners Downgrades Agios Pharma (AGIO) to Market Perform

Sep 26, 2024 07:15AM Piper Sandler Reiterates Overweight Rating on Agios Pharma (AGIO)

Sep 24, 2024 02:51PM Agios Pharma (AGIO) 2K contracts of December 40 puts trade at $1.35

Sep 11, 2024 07:00AM Agios Pharma (AGIO) Receives FDA Orphan Drug Designation for Tebapivat

Sep 10, 2024 07:22AM Piper Sandler Reiterates Overweight Rating on Agios Pharma (AGIO)

Aug 2, 2024 06:21AM Agios Pharma (AGIO) PT Raised to $55 at RBC Capital

Aug 1, 2024 06:37AM Agios Pharma (AGIO) Misses Q2 EPS by 9c

Aug 1, 2024 06:31AM Agios Pharma (AGIO) Reports Results from Phase 3 ACTIVATE-KidsT Study of Mitapivat

Jul 30, 2024 07:17AM RBC's biotech survey shows investors more bearish vs. last time

Jul 9, 2024 07:00PM 2Q24 U.S. biotech earnings preview

Jun 17, 2024 10:07AM TD Cowen Reiterates Buy Rating on Agios Pharma (AGIO)

Jun 17, 2024 07:54AM Piper Sandler Reiterates Overweight Rating on Agios Pharma (AGIO)

Jun 13, 2024 04:55PM JPMorgan Resumes Agios Pharma (AGIO) at Neutral

View More Recent Stories